NCT07934472
A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Plasma concentration of DZP in the infants at birth
Timeframe: At Birth during this study
Plasma concentration of DZP in mothers at delivery
Timeframe: At Delivery during this study
Ratio between plasma concentration of DZP between the infants and mother at birth/delivery
Timeframe: Infants: At Birth; Mothers: At Delivery during this study
Secondary (19)
Plasma concentration of DZP after birth in the infants from mothers continuing DZP treatment postpartum
Predose and postdose plasma concentrations of DZP in mothers during pregnancy
DZP plasma concentrations at 12 and 14 Weeks postpartum in mothers continuing DZP treatment postpartum
DZP plasma concentrations at 12 weeks postpartum in mothers stopping DZP treatment postpartum
Treatment-emergent adverse events (TEAEs) of mothers
Show 14 moreShow less
Serious TEAEs of mothers
TEAEs of special interest of mothers
TEAEs of special monitoring of mothers
AEs of infants
Serious AEs of infants
AEs of special interest of infants
AEs of special monitoring of infants
Pregnancy outcome
Predicted area under the curve (AUC) over the dosing interval at steady state across the second and third trimesters of pregnancy
Predicted trough plasma concentration (Ctrough) over the dosing interval at steady state across the second and third trimesters of pregnancy
Predicted maximum plasma concentration (Cmax) over the dosing interval at steady state across the second and third trimesters of pregnancy
Predicted AUC over the dosing interval at steady state across the postpartum
Predicted Ctrough over the dosing interval at steady state across the postpartum
Predicted Cmax over the dosing interval at steady state across the postpartum
Arms and interventions
Dapirolizumab pegol (DZP)Experimental
Pregnant women will receive DZP by intravenous (iv) administration during 2nd and 3rd trimester and after delivery they may continue for up to 1 year (if not breastfeeding).
Drugs: Dapirolizumab pegol (DZP)